PreCheck Begins Filling Orders for Coronavirus (COVID-19) PCR Test and Announces Distribution Agreements in Romania and Moldo...
March 20 2020 - 8:00AM
PreCheck Health Services, Inc. (OTC PINK: HLTY), a distributor of
medical screening devices for use by physicians in managing a
patient’s health, announces it has ordered and paid for 37,500 of
the Co-Diagnostics’ Coronavirus (COVID-19) PCR test kits and has
received the first 7,500 test kits to start filling orders for the
product. PreCheck has also entered into its fourth and fifth
distribution agreements with Co-Diagnostics Inc. (Nasdaq: CODX).
These agreements give the Company the distribution rights to
Co-Diagnostics’ qPCR infectious disease kits, Logix Smart COVID-19
PCR diagnostic test and Co-Dx Box™ instrument in Romania and
Moldova. This agreement follows the execution of agreements with
Co-Diagnostics for Russia, Ecuador and Panama. PreCheck’s five
combined distribution territories have an aggregate population of
188 million.
PreCheck believes Co-Diagnostics’ Coronavirus COVID-19 PCR test
is the most accurate test to detect the presence of the COVID19
infection. Co-Diagnostics has announced that it was the first
U.S. Company to obtain a CE marking for a COVID-19 test.
CE marking is a certification mark that
indicates conformity with health, safety, and environmental
protection standards for products sold within the European Economic
Area (the “EEA”). The CE marking is also found on
products sold outside the EEA that have been manufactured to EEA
standards.
Justin Anderson, CEO of PreCheck Health Services, Inc.,
commented, “Today marks a major milestone, the receipt of the first
7,500 of 37,500 test kits that we have purchased. Now we can
commence filling orders. We are pleased to expand our relationship
with Co-Diagnostics in working together to combat this global
health crisis.”
Further information is available in the Company’s regulatory
filings, which can be accessed
at www.sec.gov.
About PreCheck Health Services, Inc.
PreCheck Health Services, Inc. is a distributor of the PC8B, a
medical screening device, which it purchases from a domestic
supplier. The PC8B medical device is a screening tool for use by
physicians in managing a patient’s health.
Disclaimer for Forward-Looking Information
Certain statements contained in this press release, including,
without limitation, statements containing the words “believes,”
“anticipates,” “expects” and words of similar import, constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve both known and unknown risks and uncertainties.
The Company’s actual results may differ materially from those
anticipated in its forward-looking statements as a result of a
number of factors, including our ability to obtain substantial
funding required for our operations; our ability to market our
product to physicians, our ability to generate a gross margin from
any sales we may make; our ability to obtain government approval
for the sale of the COVID-19 tests in countries where we have
distribution rights, competition from other products which perform
similar functions, any liability that we may incur as a result of
any failure of the test kits we sell to perform as represented by
the manufacturer, any liability we may sustain as a result of
actions taken by the manufacturers of our products, any liability
we may incur as a result of the failure of our manufacturers to
have rights to the intellectual property embodied in their
products; our dependence upon a sole supplier for each of our
products and our reliance of our suppliers to protect their
intellectual property incorporated in the product we market; our
ability to obtain rights to and to market successfully market
products, our ability to develop the business of these businesses,
our ability to maintain and develop our medical practice management
business, and other risks relating to JAS Practice Management,
Inc., doing business as JAS Consulting, Inc. (“JAS”), the medical
practice management business which we acquired in December 2019,
any risk or liability resulting from our failure to file the
financial statements of JAS as required by SEC regulations, as well
as other risks contained in “Forward Looking Statements,” “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” in our Form 10-K for the year
ended December 31, 2018 and in “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” in its
Form 10-Q for the quarter ended September 30, 2019, and any
information contained in any other filings we make with the SEC. As
a result of our acquisition of JAS, our historical financial
statements, which will be included in our Form 10-K for the year
ended December 31, 2019, for periods prior to the December 19, 2019
date of acquisition will reflect the operations of JAS prior to the
date of acquisition.
Brett Maas Hayden IR (646) 536-7331
brett@haydenir.com
James Carbonara Hayden IR (646)-755-7412
james@haydenir.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Sep 2023 to Sep 2024